Shao-Lee Lin - 01 Jun 2026 Form 4/A - Amendment Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CUE
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 30 Jul 2026, 16:35:56 UTC
Original report date: 01 Jun 2026
Prior SEC filing: 07 May 2026
Next SEC filing: 10 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Shao-Lee Lin

Key filing fact

Shao-Lee Lin filed Form 4/A - Amendment for Cue Biopharma, Inc. (CUE) on 30 Jul 2026.

Key facts

This page summarizes Shao-Lee Lin's Form 4/A - Amendment filing for Cue Biopharma, Inc. (CUE).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Jul 2026, 16:35.

Change

Previous filing in this sequence was filed on 07 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001725092 Primary reporting owner

Lin Shao-Lee

Relationship: Chief Executive Officer, Director
Address: C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature: /s/ Shao-Lee Lin
Signature date: 29 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Pre-Funded Warrants (Right to Buy)

Award

Transaction value
Shares: +90,906
Change %
Price: $11.00^*
Shares after: 90,906
Date: 01 Jun 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 90,906
Exercise price: $0.001000
Footnotes: F1, F2, F3, F4

CUE transaction Derivative

Common Stock Warrants (Right to Buy)

Award

Transaction value
Shares: +45,453
Change %
Price
Shares after: 45,453
Date: 01 Jun 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 45,453
Exercise price: $11.00
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged.

Footnote F2

The securities do not have an expiration date.

Footnote F3

On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.

Footnote F4

The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.